XML 29 R18.htm IDEA: XBRL DOCUMENT

INCOME/(LOSS) PER SHARE

6 Months Ended

Jun. 30, 2021

INCOME/(LOSS) PER SHARE

INCOME/(LOSS) PER SHARE

8. INCOME/(LOSS) PER SHARE

The following table sets forth the computation of basic and diluted income/(loss) per share for the periods presented (dollars and shares in thousands, except per share data):


		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2021			2020			2021			2020
Numerator for income/(loss) per share:
Net income/(loss)		$	12,535		$	62,096		$	15,809		$	67,636
Net (income)/loss attributable to redeemable noncontrolling interests in the Operating Partnership and DownREIT Partnership			(807)			(4,291)			(961)			(4,604)
Net (income)/loss attributable to noncontrolling interests			(8)			(34)			(24)			(40)
Net income/(loss) attributable to UDR, Inc.			11,720			57,771			14,824			62,992
Distributions to preferred stockholders — Series E (Convertible)			(1,057)			(1,062)			(2,113)			(2,128)
Income/(loss) attributable to common stockholders - basic and diluted		$	10,663		$	56,709		$	12,711		$	60,864

Denominator for income/(loss) per share:
Weighted average common shares outstanding			296,842			294,970			296,821			294,850
Non-vested restricted stock awards			(253)			(260)			(257)			(266)
Denominator for basic income/(loss) per share			296,589			294,710			296,564			294,584
Incremental shares issuable from assumed conversion of unvested LTIP Units and unvested restricted stock			953			377			657			499
Denominator for diluted income/(loss) per share			297,542			295,087			297,221			295,083

Income/(loss) per weighted average common share:
Basic		$	0.04		$	0.19		$	0.04		$	0.21
Diluted		$	0.04		$	0.19		$	0.04		$	0.21

Basic income/(loss) per common share is computed based upon the weighted average number of common shares outstanding. Diluted income/(loss) per common share is computed based upon the weighted average number of common shares outstanding plus the common shares issuable from the assumed conversion of the OP Units and DownREIT Units, convertible preferred stock, stock options, unvested long-term incentive plan units (“LTIP Units”), unvested restricted stock and continuous equity program forward sales agreements. Only those instruments having a dilutive impact on our basic income/(loss) per share are included in diluted income/(loss) per share during the periods. For the three and six months ended June 30, 2021 and 2020, the effect of the conversion of the OP Units, DownREIT Units and the Company’s Series E preferred stock was not dilutive and therefore not included in the above calculation.

In July 2017, the Company entered into an ATM sales agreement under which the Company may offer and sell up to 20.0 million shares of its common stock, from time to time, to or through its sales agents and may enter into separate forward sales agreements to or through its forward purchasers. Upon entering into the ATM sales agreement, the Company simultaneously terminated the sales agreement for its prior at-the-market equity offering program, which was entered into in April 2017, which replaced the prior at-the-market equity offering program entered into in April 2012. During the six months ended June 30, 2021, the Company did not sell any shares of common stock through its ATM program, other than the forward sales described below. As of June 30, 2021, we had 9.6 million shares of common stock available for future issuance under the ATM program, including an aggregate of 4.8 million shares subject to the forward sales agreements described below.

In connection with any forward sales agreement under the Company’s ATM program, the relevant forward purchasers will borrow from third parties and, through the relevant sales agent, acting in its role as forward seller, sell a number of shares of the Company’s common stock equal to the number of shares underlying the agreement. The Company does not initially receive any proceeds from any sale of borrowed shares by the forward seller.

During the three months ended June 30, 2021, the Company entered into forward sales agreements under its ATM program for a total of 2.6 million shares of common stock at a weighted average initial forward price per share of $49.07. As of June 30, 2021, the Company had entered into forward sales agreements under its ATM program for a total of 4.8 million shares of common stock at a weighted average initial forward price per share of $46.61. The actual forward price per share to be received by the Company upon settlement will be determined on the applicable settlement date based on adjustments made to the initial forward price to reflect the then-current federal funds rate and the amount of dividends paid to holders of UDR common stock over the term of the forward sales agreement. As of June 30, 2021, no shares under the forward sales agreements have been settled. The final dates by which shares sold under the forward sales agreements must be settled range between February 23, 2022 and June 9, 2022.

In March 2021, the Company entered into forward sale agreements to sell 7.0 million shares of its common stock at an initial forward price per share of $43.51. The actual forward price per share to be received by the Company upon settlement will be determined on the applicable settlement date based on adjustments made to the initial forward price to reflect the then-current federal funds rate and the amount of dividends paid to holders of UDR common stock over the term of the forward sales agreement. As of June 30, 2021, no shares under the forward sale agreements have been settled. The final date by which shares sold under the forward sale agreements must be settled is March 29, 2022.

In June 2021, the Company entered into forward sale agreements to sell 6.1 million shares of its common stock at an initial forward price per share of $49.22. The actual forward price per share to be received by the Company upon settlement will be determined on the applicable settlement date based on adjustments made to the initial forward price to reflect the then-current federal funds rate and the amount of dividends paid to holders of UDR common stock over the term of the forward sales agreement. As of June 30, 2021, no shares under the forward sale agreements have been settled. The final date by which shares sold under the forward sale agreements must be settled is June 20, 2022.

The Company generally has the ability to determine the dates and method of settlement (i.e., gross physical settlement, net share settlement or cash settlement), subject to certain conditions and the right of the counterparty to accelerate settlement under certain circumstances. The Company currently expects to fully physically settle each forward sales agreement with the relevant forward purchaser on one or more dates specified by the Company on or prior to the maturity date of that particular forward sales agreement, in which case the Company expects to receive aggregate net cash proceeds at settlement equal to the number of shares underlying the particular forward sales agreement multiplied by the relevant forward sale price. However, subject to certain exceptions, the Company may also elect, in its discretion, to cash settle or net share settle a particular forward sales agreement, in which case the Company may not receive any proceeds (in the case of cash settlement) or will not receive any proceeds (in the case of net share settlement), and the Company may owe cash (in the case of cash settlement) or shares of UDR common stock (in the case of net share settlement) to the relevant forward purchaser.

The following table sets forth the additional shares of common stock outstanding, by equity instrument, if converted to common stock for each of the three and six months ended June 30, 2021 and 2020 (in thousands):


		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2021		2020		2021		2020
OP/DownREIT Units		22,550		22,386		22,474		22,307
Convertible preferred stock		2,918		2,953		2,918		2,982
Unvested LTIP Units and unvested restricted stock		953		377		657		499